Andrew Knudten

Andrew Knudten is Chief Operating Officer at Jaguar Gene Therapy, which is focused on advancing its pipeline of AAV9-based Gene Therapy programs targeting diseases with significant unmet need. Prior to Jaguar Gene Therapy, he was the chief technical officer and head of Technical Operations Strategy at AveXis, Inc., where he led the development and successful commercialization of Zolgensma® from a manufacturing, process development and supply chain perspective. Andrew’s biotechnology career started in 1994 at Amgen, Inc., where he served in a number of leadership roles within Protein Chemistry, Product Development, Finance and Operations. He went on to leadership roles at Novartis, Hospira and other leading companies. Andrew holds a Bachelor of Science degree in Biology and Health from Concordia University, a Master of Science degree in Cell Biology and Genetics from the University of Nebraska, Lincoln, and a Master of Business Administration degree from UCLA’s Anderson School of Management.